Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Healthtrust
Citi
Express Scripts
Federal Trade Commission
US Army

Generated: September 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,169,213

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,169,213
Title:Method of weight management
Abstract: Provided are methods of determining if an individual is a responder to treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof. Also provided are methods for selecting an individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management. Also provided are methods for weight management in an individual in need thereof. Also provided are compounds, compositions, and kits for use in a method of weight management in an individual.
Inventor(s): Sanchez; Matilde (Alexandria, VA), Shanahan; William R. (Del Mar, CA)
Assignee: Arena Pharmaceuticals, Inc. (San Diego, CA)
Application Number:14/242,442
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,169,213
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Drugs Protected by US Patent 9,169,213

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Eisai Inc BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524-001 Jul 15, 2016 RX Yes Yes   Try a Free Trial   Try a Free Trial USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT   Try a Free Trial
Eisai Inc BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524-001 Jul 15, 2016 RX Yes Yes   Try a Free Trial   Try a Free Trial USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT   Try a Free Trial
Eisai Inc BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524-001 Jul 15, 2016 RX Yes Yes   Try a Free Trial   Try a Free Trial USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT   Try a Free Trial
Eisai Inc BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524-001 Jul 15, 2016 RX Yes Yes   Try a Free Trial   Try a Free Trial USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT   Try a Free Trial
Eisai Inc BELVIQ lorcaserin hydrochloride TABLET;ORAL 022529-001 Jun 27, 2012 RX Yes Yes   Try a Free Trial   Try a Free Trial USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 9,169,213

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 088670   Try a Free Trial
Australia 2012392187   Try a Free Trial
Brazil 112015007779   Try a Free Trial
Canada 2886875   Try a Free Trial
Japan 2015534563   Try a Free Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Moodys
Healthtrust
Fuji
UBS
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.